First Manhattan’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Manhattan’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-60	Closed	-$5K	–	1697
2022 Q3	$5K	Hold	60	–	–	﹤0.01%	1302
2022 Q2	$4K	Hold	60	–	–	﹤0.01%	1355
2022 Q1	$4K	Hold	60	–	–	﹤0.01%	1405
2021 Q4	$5K	Hold	60	–	–	﹤0.01%	1368
2021 Q3	$4K	Hold	60	–	–	﹤0.01%	1418
2021 Q2	$5K	Hold	60	–	–	﹤0.01%	1381
2021 Q1	$4K	Buy	+60	New	+$4.9K	﹤0.01%	1366
2019 Q2	–	Sell	-600	Closed	-$53K	–	1366
2019 Q1	$53K	Hold	600	–	–	﹤0.01%	944
2018 Q4	$51K	Hold	600	–	–	﹤0.01%	921
2018 Q3	$58K	Hold	600	–	–	﹤0.01%	951
2018 Q2	$56K	Hold	600	–	–	﹤0.01%	933
2018 Q1	$48K	Sell	600 -625	-51%	-$53.6K	﹤0.01%	961
2017 Q4	$109K	Buy	1,225 +625	+104%	+$54.3K	﹤0.01%	829
2017 Q3	$55K	Buy	+600	New	+$53K	﹤0.01%	931

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan's BMRN Position: Q4 2022 in Review

First Manhattan sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 60 shares — an estimated $5K sold.

First Manhattan first reported a position in BMRN in Q3 2017 and held it in 14 quarters. The position peaked at $109K in Q4 2017. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

First Manhattan reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 60 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $5K.
First Manhattan first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 14 quarters.
First Manhattan's BioMarin Pharmaceuticals position peaked at $109K in Q4 2017.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.